High-risk prostate cancer: Persistent PSA after surgery linked to worse outcomes

Key clinical point: In patients with high-risk prostate cancer undergoing radical prostatectomy, persistent prostate-specific antigen (PSA) is associated with poor oncological outcomes. Early salvage radiotherapy with or without androgen deprivation therapy (ADT) improves survival in patients with persistent PSA.

Major finding: In patients with persistent vs. undetectable PSA, estimated clinical progression-free survival (63.8% vs 93.5%; P < .0001) and overall survival (OS; 54.0% vs 83.2%; P < .0001) were significantly lower at 10 years. In patients with persistent PSA, ADT alone vs salvage radiotherapy was associated with a higher risk for worse OS (hazard ratio, 4.7; P < .0001).

Study details: A retrospective study of 414 consecutive patients with high-risk prostate cancer who underwent radical prostatectomy; 125 patients had persistent PSA.

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Milonas D et al. Clin Transl Oncol. 2021 Aug 28. doi: 10.1007/s12094-021-02700-y.

Key clinical point: In patients with high-risk prostate cancer undergoing radical prostatectomy, persistent prostate-specific antigen (PSA) is associated with poor oncological outcomes. Early salvage radiotherapy with or without androgen deprivation therapy (ADT) improves survival in patients with persistent PSA.

Major finding: In patients with persistent vs. undetectable PSA, estimated clinical progression-free survival (63.8% vs 93.5%; P < .0001) and overall survival (OS; 54.0% vs 83.2%; P < .0001) were significantly lower at 10 years. In patients with persistent PSA, ADT alone vs salvage radiotherapy was associated with a higher risk for worse OS (hazard ratio, 4.7; P < .0001).

Study details: A retrospective study of 414 consecutive patients with high-risk prostate cancer who underwent radical prostatectomy; 125 patients had persistent PSA.

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Milonas D et al. Clin Transl Oncol. 2021 Aug 28. doi: 10.1007/s12094-021-02700-y.

Key clinical point: In patients with high-risk prostate cancer undergoing radical prostatectomy, persistent prostate-specific antigen (PSA) is associated with poor oncological outcomes. Early salvage radiotherapy with or without androgen deprivation therapy (ADT) improves survival in patients with persistent PSA.

Major finding: In patients with persistent vs. undetectable PSA, estimated clinical progression-free survival (63.8% vs 93.5%; P < .0001) and overall survival (OS; 54.0% vs 83.2%; P < .0001) were significantly lower at 10 years. In patients with persistent PSA, ADT alone vs salvage radiotherapy was associated with a higher risk for worse OS (hazard ratio, 4.7; P < .0001).

Study details: A retrospective study of 414 consecutive patients with high-risk prostate cancer who underwent radical prostatectomy; 125 patients had persistent PSA.

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Milonas D et al. Clin Transl Oncol. 2021 Aug 28. doi: 10.1007/s12094-021-02700-y.